CircPAN3 mediates drug resistance in acute myeloid leukemia through the miR-153-5p/miR-183-5p-XIAP axis
Acute myeloid leukemia (AML) is one of the most common hematological malignancies [1,2]. Despite the application of new molecular targeted drugs and progress of allogeneic hematopoietic stem cell transplantation, chemoradiotherapy is still the mainstay for the treatment of AML. However, AML cells are demonstrated to unavoidably develop primary or secondary chemo-resistance, thereby resulting in refractory and recurrent disease in patients. So far, most clinical trials of chemotherapy showed very limited benefits for refractory and recurrent AML [3].
Source: Experimental Hematology - Category: Hematology Authors: Jin Shang, Wei-Min Chen, Zhi-Hong Wang, Tian-Nan Wei, Zhi-Zhong Chen, Wen-Bing Wu Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Clinical Trials | Hematology | Leukemia | Stem Cell Therapy | Stem Cells | Transplants